Integra LifeSciences Holdings (IART) 1999年年度报告「NASDAQ」.pdf

《Integra LifeSciences Holdings (IART) 1999年年度报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《Integra LifeSciences Holdings (IART) 1999年年度报告「NASDAQ」.pdf（80页珍藏版）》请在三个皮匠报告上搜索。

1、1999 Annual Report toStockholdersPresidents MessageTo Our Stockholders:This was a year of great strategic change for Integra.In 1999,we initiated a repositioning of our business to focus selectively onattractive niche markets.Implementation of this strategy included the purchase of the NeuroCare Gro

2、up of companies in March 1999 andthe execution of an agreement with Johnson&Johnson Medical,Division of Ethicon,Inc.,that provides them with exclusive marketingand distribution rights to INTEGRAs Artificial Skin worldwide,excluding Japan.As a result of these transactions and two additionalacquisitio

3、ns in early 2000,we formed our Integra NeuroSciences segment and reorganized the remainder of our products into our IntegraLifeSciences segment.Our efforts have had their rewards.In 1999,we sold over 1,000 different products to almost 2000 hospitals and other customers inmore than 60 countries.Total

4、 revenues increased$25.0 million,or 143%,from$17.5 million in 1998 to$42.5 million in 1999.The increasewas primarily a result of the NeuroCare acquisition.A majority of the products in the Integra NeuroSciences segment,which accounted for 54%of our total revenues in 1999,wereacquired in the NeuroCar

5、e acquisition.Integra NeuroSciences is a leading provider of implants,instruments and monitors used inneurosurgery,neurotrauma and related critical care.Integra NeuroSciences sells its products in the United States primarily through a directsales organization,and through a network of specialized dis

6、tributors outside the United States.The Integra LifeSciences segment,which accounted for 46%of our total revenues in 1999,now operates as a provider of innovativeproducts and development activities through strategic alliances with marketing partners and distributors.The Johnson&Johnsonagreement allo